Cleared Traditional

K190616 - VITEK 2 AST-Gram Positive Dalbavancin (<= 0.015 - >= 1 µg/mL) (FDA 510(k) Clearance)

Jun 2019
Decision
87d
Days
Class 2
Risk

K190616 is an FDA 510(k) clearance for the VITEK 2 AST-Gram Positive Dalbavancin (<= 0.015 - >= 1 µg/mL). This device is classified as a System, Test, Automated, Antimicrobial Susceptibility, Short Incubation (Class II - Special Controls, product code LON).

Submitted by bioMerieux, Inc. (Hazelwood, US). The FDA issued a Cleared decision on June 6, 2019, 87 days after receiving the submission on March 11, 2019.

This device falls under the Microbiology FDA review panel. Regulated under 21 CFR 866.1645.

Submission Details

510(k) Number K190616 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received March 11, 2019
Decision Date June 06, 2019
Days to Decision 87 days
Submission Type Traditional
Review Panel Microbiology (MI)
Summary Summary PDF

Device Classification

Product Code LON — System, Test, Automated, Antimicrobial Susceptibility, Short Incubation
Device Class Class II - Special Controls
CFR Regulation 21 CFR 866.1645

Similar Devices — LON System, Test, Automated, Antimicrobial Susceptibility, Short Incubation

All 25
VITEK 2 AST-Gram Negative Cefazolin (=<1-=>32 µg/mL)
K251579 · bioMerieux, Inc. · Aug 2025
BD Phoenix Automated Microbiology System - GN Eravacycline (0.125-2 µg/mL)
K251713 · Becton, Dickinson and Company · Aug 2025
BD Phoenix™ Automated Microbiology System - GN Imipenem-relebactam (0.0625/4 - 16/4 µg/mL)
K250447 · Becton, Dickinson and Company · May 2025
VITEK COMPACT PRO
K234012 · bioMerieux, Inc. · Mar 2025
BD Phoenix™ Automated Microbiology System
K250344 · Becton, Dickinson and Company · Mar 2025
BD Phoenix™ Automated Microbiology System - GN Ciprofloxacin (0.0156–4 µg/mL)
K233986 · Becton, Dickinson and Company · Mar 2024